Restoret is named as an intervention in 3 current clinical trials in our USA, UK, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Turkey, Australia, Israel, Brazil, Mexico and Japan registers. 1 is recruiting patients now. The most common phase is Phase 2/3. The lead sponsor is EyeBiotech Ltd. The most-studied condition is Diabetic Macular Edema (DME).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887 · Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
|
Phase 2 | Recruiting | EyeBiotech Ltd | USA |
|
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045 · ClinicalTrials.gov ↗ · Diabetic Macular Edema (DME)
|
Phase 2/3 | Active, closed | EyeBiotech Ltd | UK, USA, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Turkey, Australia, Israel |
|
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080 · ClinicalTrials.gov ↗ · Diabetic Macular Edema (DME)
|
Phase 2/3 | Active, closed | EyeBiotech Ltd | USA, Brazil, Mexico, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| EyeBiotech Ltd | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, UK, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Turkey, Australia, Israel, Brazil, Mexico and Japan registers name Restoret (also registered as EYE103) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is EyeBiotech Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Restoret works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Restoret works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Restoret (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.